H. Lundbeck, Significant phase II clinical results for gaboxadol (first SEGA sleep agent) announced at the APA conference

Gaboxadol demonstrated clear improvement on several clinical end-points as well as enhancement of slow wave sleep in studies in primary insomnia and transient insomnia.